Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C24H31FO6.H2O |
Molecular Weight | 887.0108 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO.[H][C@@]67C[C@@]8([H])[C@]9([H])C[C@H](F)C%10=CC(=O)C=C[C@]%10(C)[C@@]9([H])[C@@H](O)C[C@]8(C)[C@@]6(OC(C)(C)O7)C(=O)CO
InChI
InChIKey=MIXMJCQRHVAJIO-TZHJZOAOSA-N
InChI=1S/2C24H31FO6.H2O/c2*1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26;/h2*5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3;1H2/t2*13-,14-,16-,17-,19+,20+,22-,23-,24+;/m00./s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00180Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/flunisolide.html
Sources: http://www.drugbank.ca/drugs/DB00180
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/flunisolide.html
Flunisolide is a synthetic corticosteroid. It is administered either as an oral metered-dose inhaler for the treatment of asthma or as a nasal spray for treating allergic rhinitis. Corticosteroids are naturally occurring hormones that prevent or suppress inflammation and immune responses. When given as an intranasal spray, flunisolide reduces watery nasal discharge (rhinorrhea), nasal congestion, postnasal drip, sneezing, and itching oat the back of the throat that are common allergic symptoms. Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin. It is used for the maintenance treatment of asthma as a prophylactic therapy. Flunisolide is marketed as AeroBid, Nasalide, Nasarel.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00180 |
|||
Target ID: CHEMBL614636 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9756205 |
32.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FLUNISOLIDE Approved UseFlunisolide Nasal Solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 ng/mL |
160 μg 2 times / day multiple, respiratory dose: 160 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
FLUNISOLIDE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.2 ng × h/mL |
160 μg 2 times / day multiple, respiratory dose: 160 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
FLUNISOLIDE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9505980 |
0.5 mg single, respiratory dose: 0.5 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
FLUNISOLIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9505980 |
0.5 mg single, respiratory dose: 0.5 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
FLUNISOLIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Other AEs: Headache, Fever... Other AEs: Headache (13.8%) Sources: Fever (3.7%) Allergic reaction (4.6%) Pain (4.6%) Accidental injury (3.7%) Infection (0.9%) Back pain (3.2%) Vomiting (4.6%) Dyspepsia (3.2%) Pharyngitis (16.6%) Rhinitis (15.7%) Cough increased (5.5%) Sinusitis (4.1%) Epistaxis (0.9%) Rash (3.7%) Urinary tract infection (0.9%) |
320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Other AEs: Headache, Fever... Other AEs: Headache (8.8%) Sources: Fever (0.9%) Allergic reaction (4.4%) Pain (1.8%) Accidental injury (3.5%) Infection (0.9%) Back pain (1.8%) Dyspepsia (3.5%) Pharyngitis (16.8%) Rhinitis (3.5%) Cough increased (1.8%) Sinusitis (8.8%) Rash (1.8%) Urinary tract infection (3.5%) |
80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Other AEs: Headache, Fever... Other AEs: Headache (9%) Sources: Fever (6.9%) Allergic reaction (4.2%) Pain (2.6%) Accidental injury (3.7%) Infection (3.7%) Back pain (0.5%) Vomiting (4.2%) Dyspepsia (2.1%) Pharyngitis (17.5%) Rhinitis (9%) Cough increased (8.5%) Sinusitis (7.4%) Epistaxis (3.2%) Rash (2.6%) Urinary tract infection (1.1%) |
85 ug 2 times / day steady, respiratory Dose: 85 ug, 2 times / day Route: respiratory Route: steady Dose: 85 ug, 2 times / day Sources: |
unhealthy, 6-11 years n = 510 Health Status: unhealthy Condition: asthma Age Group: 6-11 years Population Size: 510 Sources: |
Disc. AE: Asthma, Pharyngitis... AEs leading to discontinuation/dose reduction: Asthma (10%) Sources: Pharyngitis (1.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Epistaxis | 0.9% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Infection | 0.9% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Urinary tract infection | 0.9% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Headache | 13.8% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Rhinitis | 15.7% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Pharyngitis | 16.6% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Back pain | 3.2% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Dyspepsia | 3.2% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Accidental injury | 3.7% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Fever | 3.7% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Rash | 3.7% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Sinusitis | 4.1% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Allergic reaction | 4.6% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Pain | 4.6% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Vomiting | 4.6% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Cough increased | 5.5% | 160 ug 2 times / day steady, respiratory (starting) Recommended Dose: 160 ug, 2 times / day Route: respiratory Route: steady Dose: 160 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 217 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 217 Sources: |
Fever | 0.9% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Infection | 0.9% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Back pain | 1.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Cough increased | 1.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Pain | 1.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Rash | 1.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Pharyngitis | 16.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Accidental injury | 3.5% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Dyspepsia | 3.5% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Rhinitis | 3.5% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Urinary tract infection | 3.5% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Allergic reaction | 4.4% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Headache | 8.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Sinusitis | 8.8% | 320 ug 2 times / day steady, respiratory (starting) Recommended Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 113 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 113 Sources: |
Back pain | 0.5% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Urinary tract infection | 1.1% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Pharyngitis | 17.5% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Dyspepsia | 2.1% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Pain | 2.6% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Rash | 2.6% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Epistaxis | 3.2% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Accidental injury | 3.7% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Infection | 3.7% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Allergic reaction | 4.2% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Vomiting | 4.2% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Fever | 6.9% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Sinusitis | 7.4% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Cough increased | 8.5% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Headache | 9% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Rhinitis | 9% | 80 ug 2 times / day steady, respiratory (starting) Recommended Dose: 80 ug, 2 times / day Route: respiratory Route: steady Dose: 80 ug, 2 times / day Sources: |
unhealthy, 4-78 years n = 189 Health Status: unhealthy Condition: asthma Age Group: 4-78 years Sex: M+F Population Size: 189 Sources: |
Pharyngitis | 1.7% Disc. AE |
85 ug 2 times / day steady, respiratory Dose: 85 ug, 2 times / day Route: respiratory Route: steady Dose: 85 ug, 2 times / day Sources: |
unhealthy, 6-11 years n = 510 Health Status: unhealthy Condition: asthma Age Group: 6-11 years Population Size: 510 Sources: |
Asthma | 10% Disc. AE |
85 ug 2 times / day steady, respiratory Dose: 85 ug, 2 times / day Route: respiratory Route: steady Dose: 85 ug, 2 times / day Sources: |
unhealthy, 6-11 years n = 510 Health Status: unhealthy Condition: asthma Age Group: 6-11 years Population Size: 510 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? | 2001 |
|
e-NO peak versus e-NO plateau values in evaluating e-NO production in steroid-naive and in steroid-treated asthmatic children and in detecting response to inhaled steroid treatment. | 2001 Jan |
|
Pharmacokinetics of intranasal corticosteroids. | 2001 Jul |
|
Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. | 2001 Nov |
|
Adrenal suppression with inhaled corticosteroids. | 2001 Nov |
|
Flunisolide HFA. | 2002 |
|
Nasal cellularity in 183 unselected schoolchildren aged 9 to 11 years. | 2002 Dec |
|
Therapeutic significance of distal airway inflammation in asthma. | 2002 Feb |
|
Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. | 2002 Jul |
|
A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. | 2002 Mar |
|
[Steroid sprays in non-infectious rhinitis and sinusitis. Proper and regular spraying does not damage the nasal mucosa]. | 2002 Mar 7 |
|
Intranasal corticosteroids for allergic rhinitis. | 2002 Nov |
|
Multiple-dose proportionality study of flunisolide hydrofluoroalkane. | 2002 Sep-Oct |
|
Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. | 2003 Jul |
|
Inappropriate use of anti-asthmatic drugs in the Italian paediatric population. | 2003 Oct |
|
Effect of topical nasal corticosteroids on patients with chronic fatigue syndrome and rhinitis. | 2003 Sep |
|
A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. | 2003 Sep |
|
Significant receptor affinities of metabolites and a degradation product of mometasone furoate. | 2004 Jul 22 |
|
Interactions between rhinitis and asthma. | 2004 Mar-Apr |
|
[Hydrofluoroalkane as a propellant for pressurized metered-dose inhalers: history, pulmonary deposition, pharmacokinetics, efficacy and safety]. | 2004 Nov-Dec |
|
Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. | 2005 Nov |
|
Use of Respimat Soft Mist inhaler in COPD patients. | 2006 |
|
Pharmacological treatment of chronic obstructive pulmonary disease. | 2006 |
|
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. | 2006 Jan 24 |
|
Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma. | 2006 Mar |
|
Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells. | 2006 Mar 17 |
|
Hypertrichosis as a side effect of inhaled steroids in children. | 2007 Apr |
|
Topical nasal steroids for intermittent and persistent allergic rhinitis in children. | 2007 Jan 24 |
|
Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. | 2007 Jan-Feb |
|
Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects. | 2007 Jul |
|
Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency). | 2007 Jul-Aug |
|
A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. | 2007 Nov-Dec |
|
Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis. | 2008 Jul |
|
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. | 2008 Nov 4 |
|
Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. | 2008 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/flunisolide-nasal.html
Initial dose: 2 sprays in each nostril 2 times a day.
If needed, this dose may be increased to 2 sprays in each nostril 3 times a day.
Maximum total daily doses should not exceed 8 sprays in each nostril.
Route of Administration:
Nasal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20528590
Flunisolide at all the tested concentrations ((0.1 to 10 uM) effectively inhibited ICAM-1 expression and GM-CSF and IL-5 release. The percent inhibition induced by the highest flunisolide concentration (10 uM) for the various BEAS-2B functions was 30%, 60%, and 70%, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR01AD04
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
||
|
WHO-ATC |
R03BA03
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
||
|
WHO-ATC |
R01AD04
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
||
|
WHO-VATC |
QR03BA03
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7076
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
C29054
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
SUB13899MIG
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
11954221
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
1274505
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
1298840
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
DTXSID30998562
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
77326-96-6
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
QK4DYS664X
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL1512
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
FLUNISOLIDE
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
5106
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
757871
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
QK4DYS664X
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
C007734
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
DB00180
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
25120
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
ALTERNATIVE | |||
|
Flunisolide
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY | |||
|
1201
Created by
admin on Fri Dec 15 15:33:07 GMT 2023 , Edited by admin on Fri Dec 15 15:33:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD